Discover more near‑term opportunities with better event intelligence.
Fundz combines its own real-time funding and M&A intelligence with executive moves, hiring shifts and other company changes, weighs each signal against your ideal customer profile, and delivers a ranked daily shortlist with the context and decision maker to contact. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
OracleSnowflakeCloudflareLinkedInGoogleSalesforce
★★★★★4.8/5 on G2· Since 2015
ALK expands strategic partnership with Catalent for tablet production, committing approximately DKK 500 million for capacity expansion over three years.
PRIVATESep 30, 2026
Amount Raised
DKK500 Million
Round Type
Venture
Capital Region Of DenmarkBiotechnologyHealth Care
Description
ALK has announced an expanded agreement with Catalent for contract production, ensuring long-term access to Catalent's Zydis® technology. The extended partnership aims to enhance ALK's tablet production capacity significantly. The total payments to Catalent will be around DKK 500 million, activated over three years. This capacity expansion is crucial for meeting the future demand for ALK's SLIT-tablet portfolio.
Company Information
Company
ALK
Location
Capital Region Of Denmark, Denmark
About
ALK is a global, research-driven pharmaceutical company that focuses on the prevention, diagnosis, and treatment of allergies. It markets allergy immunotherapy treatments and other products and services for people with allergies and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,600 people worldwide.
Fundz sees it the moment ALK raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.